Moreover, it has been reported that some cell signaling pathways and histological changes not only involved in transactivation of PAR2 and EGFR, but also promoted gefitinib resistance in NSCLC (Michel et al., 2014; Rotow and Bivona, 2017). Here, F2RL1 is linked to non-small cell lung carcinoma.